CALiBRe trial

Updated 17 Jan 2018
Chief investigator - Professor Peter Hillmen, St James's University Hospital
An assessment of the mechanism of action of CAL-101 in B-cell receptor pathway inhibition in CLL
Award start date: 01 Feb 2015
Recruitment start date: 13 Jul 2015
Award duration: 5 years

At the moment bone marrow transplantation is the only cure for CLL, but some people may not be able to undergo this treatment because they are too frail. Chemotherapy can be effective, but can have serious side effects especially in older people.

Researchers are looking at how a biological drug called idelalisib (also known as CAL-101) works for people with chronic lymphocytic leukaemia (CLL). Idelalisib is type of drug called a PI3K inhibitor. By blocking the PI3K protein, idelalisib can stop cancer cells growing. There have been other trials of idelalisib for people with CLL but this trial aims to find out exactly how it works so doctors can develop rational therapy combinations.

The aims of this trial are to:

  • Find out how idelalisib works in the body to reduce the number of CLL cells
  • Find out how people with CLL respond to idelalisib
  • Identify people who would respond well to idelalisib

You may be eligible to join this trial if:

  • You have CLL and need treatment
  • You have CLL that has come back after treatment (relapsed) or continued to get worse during treatment (refractory)
  • You are at least 18 years old